Hemab Therapeutics Holdings Stock
Hemab Therapeutics Holdings, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Benny Sorensen
- Employees
- 59
- Market cap
- $1.4 B
- IPO
- 01/05/2026
Hemab Therapeutics Holdings, Inc. is a biotechnology company operating within the healthcare sector. Headquartered in Cambridge, Massachusetts, the firm was established in 2020 and operates in both the United States and Denmark. The company focuses on transforming the treatment of blood coagulation disorders through…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Hemab Therapeutics Holdings stock: price history
1D
-7.5%
1W
-4.9%
1M
-26.6%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Hemab Therapeutics Holdings
Analyst assessment of Hemab Therapeutics Holdings
PRICE TARGET LOW
US$36.00
CONSENSUS
US$51.40
MEDIAN
US$50.00
PRICE TARGET HIGH
US$64.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 12/08/2026
Hemab Therapeutics Holdings stock metrics
P/E
-22.95
P/B
1.99
EV/EBITDA
-23.58
RETURN ON EQUITY
-5.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
43.5%
FLOAT SHARES
20,311,830
AVG. DAILY VOLUME (30D)
551,705
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
Institutional holders
Comparable stocks
Frequently asked questions about Hemab Therapeutics Holdings stock
What does Hemab Therapeutics Holdings do?
Hemab Therapeutics Holdings, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Benny Sorensen, the company employs around 59 people.
The IPO was on 01/05/2026; the stock trades on NASDAQ under the ticker COAG.
What do analysts say about Hemab Therapeutics Holdings stock?
3 analysts rate the stock, the consensus is Buy (as of 12/08/2026).
The average price target is US$51.40, ranging from US$36.00 to US$64.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
When does Hemab Therapeutics Holdings report next?
The next earnings date is 10/11/2026.
Does Hemab Therapeutics Holdings pay a dividend?
No, Hemab Therapeutics Holdings currently does not pay a dividend.
Which stocks are comparable to Hemab Therapeutics Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Hemab Therapeutics Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Hemab Therapeutics Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.